Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab), which was approved by the FDA for the same HCC indication in September 2017.

The trial, which involved 93 patients across multiple sites in the US, Europe, and Australia, aims to evaluate the treatment's anti-tumor activity ... with Merck's KEYTRUDA® for treating certain ...

“Keytruda is not for everyone,” says Dr. Anna Pavlick, medical oncologist at Weill Cornell Medicine. She often has patients request the immunotherapy drug in response to a commercial they’ve seen. It ...

s Keytruda for melanoma and non-small cell lung cancer until the biotech halted this work in late 2023. With the iNKT and adenosine receptor agonists now pushed out, Portage doesn’t appear to ...

This was the site of an injury he sustained five months earlier while removing a patient's malignant abdominal tumor. The lump in the surgeon's hand measured 1.2 inches (3 centimeters) in diameter.

Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials of Opdivo and Keytruda as first-line agents in advanced or metastatic melanoma in which 10-year overall survival topped 40% ...

Indeed there was a small tumor in Timchak's pancreas, but it turned out to be one that could be removed surgically. "The reason this is so different is it has a much slower growth rate and doesn't ...

with no EGFR or ALK genomic tumor aberrations, is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more ...